文献速递免疫规划卫生政策与健康促进

疫苗试验中个体受试者揭盲的考量

Considerations for unblinding individual study participants during vaccine trials.
PubMed 文献 · Vaccine · 2023-04-28

本文综述了疫苗试验中个体受试者揭盲的适当理由,指出过早揭盲虽少见报告,但可干扰试验,引起其他受试者担忧和脱落,或导致「伪揭盲」。作者认为监管指南应区分疫苗试验与药物试验,并认识到疫苗研究中个体受试者揭盲在免疫接种后不良事件管理中很少需要。

要点

  • 个体受试者过早揭盲可干扰疫苗试验,引起其他受试者担忧和脱落。
  • 揭盲可导致「伪揭盲」,即受试者或研究者过度解读某些症状与接种研究产品相关。
  • 监管指南应区分疫苗试验与药物试验,疫苗研究中个体揭盲在免疫接种后不良事件管理中很少需要。

核心结论

  • 疫苗试验中个体受试者揭盲在免疫接种后不良事件管理中很少需要,监管指南应区分疫苗试验与药物试验。

研究设计与样本

  • 本文为综述,总结疫苗试验中揭盲的适当理由。

主要发现

  • 个体受试者过早揭盲在出版物中罕见报告,但可干扰疫苗试验,引起其他受试者担忧和脱落,或导致「伪揭盲」。

关键数值与推荐

  • 监管指南可通过区分疫苗试验与药物试验的指导来改进。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Premature unblinding of individual participants is rarely reported in publications, but such unblinding can disrupt vaccine trials by causing worry and drop-out of other participants or "pseudo unblinding," in which participants or investigators over-interpret certain symptoms as being related to receiving an investigational product. This review summarizes appropriate reasons for unblinding in vaccine trials. Regulatory guidance could be improved by distinguishing guidance for vaccine trials from drug trials, with the recognition that unblinding individual participants in vaccine studies is rarely needed for management of adverse events following immunization.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Halsey N, Evans S, Santosham M, et al. Considerations for unblinding individual study participants during vaccine trials. Vaccine. 2023. PMID: 37121805. doi:10.1016/j.vaccine.2023.04.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。